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Abstract: Exercise-induced bronchospasm (EIB) can represent a substantial barrier to   physical 
activity. We present the cases of two patients with EIB, one with asthma, and one without 
asthma, who were evaluated at our primary care practice. The first case was a 44-year-old man 
with a history of seasonal allergic rhinitis but no asthma, who reported difficulty breathing 
when playing tennis. The second case was a 45-year-old woman who presented with persistent, 
generally well-controlled asthma, who was now experiencing bouts of coughing and wheezing 
during exercise. In both cases, an exercise challenge was used to diagnose EIB, and patients 
were prescribed a short-acting beta agonist to be used immediately before initiating exercise. 
EIB is a frequently encountered problem among patients presenting to primary care specialists. 
Affected patients should be made aware of the importance of proactive treatment with a short-
acting beta agonist before initiating any exercise.
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Introduction
All patients should be encouraged to maintain an appropriate exercise program. In adults 
aged 18–65 years with no underlying chronic disease, such an exercise program should 
consist of 30 minutes of moderate-intensity physical activity at least 5 days per week 
or vigorous-intensity exercise at least 3 days per week (www.exerciseismedicine.org). 
Given the recent increase in focus on preventive care, and the importance of physical 
activity for general health and wellness, exercise-induced bronchospasm (EIB) may 
represent a substantial barrier to physical activity in affected patients.
Although up to 90% of patients with asthma have been reported to have EIB, as 
many as 10% of patients who have no overt respiratory dysfunction may develop EIB. 
For patients with asthma, exercise-induced asthma has also been used to describe 
this condition, although many physicians believe this term is a misnomer because it 
seems to imply that exercise causes rather than exacerbates or triggers an attack of 
asthma. EIB is defined as a 15% decrease in peak expiratory flow or forced expira-
tory volume in 1 second (FEV1) after physical exertion that increases baseline heart 
rate to 80% of maximum for 4–6 minutes,1 compared with pre-exercise baseline. This 
condition usually lasts 15–20 minutes after starting or shortly after completing mod-
erately vigorous exercise.2,3 The mechanism underlying this effect is not fully under-
stood, but the fundamental trigger is thought to involve drying and cooling of airways 
during exercise. This can cause sensitized mast cells to release pro-inflammatory 
mediators, which ultimately may cause bronchospasm.2International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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The fairly broad incidence of EIB strongly suggests 
that the majority of physicians in primary care practice will 
regularly encounter patients with EIB. Indeed, this condition 
is recognized as having appropriate management options by 
most primary care specialists. Despite the apparently uncom-
plicated nature of EIB as perceived by physicians, however, 
many patients are uncertain about how to manage this con-
dition effectively. This may reflect their lack of awareness 
regarding existing treatment guidelines and the effective use 
of inhaled short-acting beta agonist (SABA) bronchodilators 
to mitigate exercise-induced respiratory symptoms due to 
bronchospasm.1 We present the cases of two patients with 
EIB, one with asthma, and one without asthma, who were 
recently evaluated at our primary care practice.
Case presentation
Case 1
A 44-year-old male with a history of seasonal allergic rhinitis, 
no smoking history, and no diagnosis of asthma presented 
to his primary care specialist reporting chest tightness, 
  difficulty breathing, and wheezing when playing tennis. 
These respiratory symptoms only occurred with moderate-to-
vigorous activity. The symptoms were moderate but seemed 
to resolve with rest. The patient had a very active lifestyle, 
with a body mass index (BMI) of 25 but was experiencing 
increased shortness of breath when running on the tennis 
court once or twice a week. During intense exercise he would 
experience exercise-related dyspnea. Routine physical exam 
and diagnostic testing ruled out cardiovascular disease. 
  Pulmonary function tests were ordered and revealed normal 
flow volume loop, normal lung volumes, and FEV1 that 
was 95% of predicted. The physician further requested a 
pulmonary exercise study using a treadmill, which showed 
a .15% decline in FEV1 within 5 minutes after completing 
the exercise (Figure 1). Based on both medical history and 
exercise study results, the patient was provided with a SABA 
inhaler and instructed to use it at least 5 minutes before start-
ing to exercise. The physician discussed with the patient that 
a warm-up period before exercise may reduce the degree of 
EIB and that a mask or scarf over the mouth may attenuate 
cold air-induced EIB. On follow-up, the patient no longer 
reported respiratory-related symptoms after exercise when 
he remembered to take his SABA prior to exercise.
Case 2
A 45-year-old woman presented to her primary care special-
ist with persistent asthma, which had been well controlled 
on low-to-medium dose-inhaled corticosteroid (ICS). 
The   physician confirmed that the patient was taking her 
ICS as directed and that she had access to a rescue medica-
tion (albuterol). She had recently joined a gym where she 
participated in a strenuous aerobic exercise program two to 
three times a week; however, during each exercise session 
she experienced repeated bouts of coughing and wheezing, 
which forced her to take a break from the exercise. She denied 
experiencing shortness of breath, cough, or wheezing at night 
or at any other time except when exercising. Her baseline 
pulmonary function testing at rest was normal, and she had 
no history of emergency room visits, hospitalizations, or 
exacerbations of asthma requiring oral corticosteroids. The 
patient was frustrated with her inability to exercise vigor-
ously and did not feel integrated with her peer group at the 
gym. She was not motivated to attend the most recent aerobic 
session because of her concern that she would not be able 
to keep up with the group exercise activity. Her primary 
care specialist ordered a pulmonary exercise study using a 
treadmill, which showed a 20% decline in FEV1 measured 
when cough and shortness of breath occurred during the 
exercise. The physician diagnosed EIB and educated the 
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patient on the importance of taking her prescribed rescue 
medication prior to exercise; two puffs to be taken at least 
5 minutes before each aerobic session to prevent the onset 
of her exercise-induced breathing difficulties. At follow-up 
1 month later, the physician confirmed that the patient was 
taking her prescribed medications as directed for her asthma, 
that she was taking her albuterol prior to exercise, and that 
there were no other signs that she was experiencing asthma 
symptoms daily. The patient reported that she could partici-
pate fully in the aerobics session with no further episodes 
of breathing difficulty and did not experience any asthma 
symptoms with normal activities.
Discussion
Results from the recent EIB Landmark Survey (www.
eiblandmarksurvey.com)4 highlight the broad impact of EIB 
on patients’ lives, including those without underlying asthma. 
The survey identifies exercise as the most common trigger 
for asthma symptoms, with almost one-third of all asthma 
patients reporting that exercise can trigger or exacerbate an 
asthma attack. Nearly half of respondents (46%) report that 
their health interferes with their ability to participate in sports 
or recreation. As part of the EIB Landmark Survey, a general 
population cross-sectional survey was also done, in which 
more than one-quarter of all adult participants reported respi-
ratory symptoms during or after physical activity, although 
less than 20% had actually been diagnosed with exercise-
induced asthma or EIB. The EIB Landmark Survey also 
confirmed that patients’ understanding of exercise-related 
bronchospasm and its management differed from that of their 
health care providers. This is highlighted by the fact that only 
41% of patients with exercise-related symptoms said that 
they took quick-relief medication at least sometimes before 
exercising, even though the standard treatment recommenda-
tion is to use a SABA medication at least 5 minutes before 
exercising. This lack of appropriate, preventative treatment in 
many patients may reflect misunderstanding between physi-
cians and patients regarding proper management of EIB.
The significant manner in which asthma and EIB can 
affect quality of life is highlighted in the cases described 
in this report. Patients with EIB are less likely to engage in 
recreational activity and are, therefore, at risk of having 
increased BMI and its potential negative health sequelae. 
Furthermore, patients with seasonal allergic rhinitis, such as 
the example in Case 1, may be predisposed to EIB, with an 
estimated 40% of patients with allergic rhinitis also show-
ing symptoms of EIB.5 In patients with underlying asthma, 
participation in physical activity without experiencing asthma 
symptoms is an important element of both optimal asthma 
management and quality of life. Therefore, EIB should be 
recognized and treated proactively to minimize barriers to 
participation in vigorous activities.
Guidelines for the Diagnosis and Management of Asthma 
indicate that patients with EIB should be monitored regu-
larly to ensure that they have no symptoms of asthma in the 
absence of exercise.1 An exercise challenge test is often used 
for diagnosis because use of medical history alone lacks 
diagnostic accuracy and may result in false-positive or false-
negative diagnoses. Formal bronchoprovocation testing using 
eucapnic voluntary hyperventilation is the preferred method 
for diagnosis. In patients diagnosed with EIB, prophylactic 
treatment with a SABA bronchodilator before starting exer-
cise is recommended and is reported to control symptoms in 
80%–95% of asthma patients.1,5 Prophylactic bronchodilator 
medication may also be necessary in asthma patients who 
are stabilized on ICS maintenance therapy. As highlighted in 
Case 2, patients with mild, persistent asthma and concurrent 
EIB may require both an ICS to maintain adequate mainte-
nance control and a SABA before exercise so that they do not 
develop asthma symptoms. In patients with chronic asthma, 
EIB can indicate poor underlying disease control1,6 and, 
hence, such patients should receive a global assessment of 
asthma management to ensure that they are taking their cur-
rent medications as indicated. Furthermore, patients with EIB 
should also be educated on nonpharmacologic interventions 
that can be used to decrease the likelihood of an EIB episode. 
A warm-up period before exercise may reduce the degree of 
EIB, and a mask or scarf over the mouth may attenuate cold 
air-induced EIB.1,6 Finally, follow-up care is crucial, with 
re-evaluation of inhalation technique, the potential need for 
additional medication, availability of rescue medication, and 
ultimately, reassessment of the diagnosis in those patients 
who continue to show exercise-related symptoms.1,6
Conclusion
EIB is frequently encountered among patients presenting to 
primary care specialists. Effective management strategies 
are well established and can allow healthy levels of activity 
for improving quality of life. Primary care specialists should 
ensure that patients with EIB are aware of the importance 
of preventative treatment with a SABA before initiating 
exercise.
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